CDKN2A and central nervous system cancer: The 2341 cell line of BRAFV600E-mutated and CDKN2A-deleted glioma injected into both immunodeficient (NSG) and immunocompetent (FVB/N) mice have revealed successful engraftment and has been critical for the preclinical assessment of experimental therapeutics (57).